Med Lasers.  2022 Jun;11(2):84-91. 10.25289/ML.2022.11.2.84.

Photodynamic therapy for SNU-80 anaplastic thyroid cancer cells

Affiliations
  • 1epartment of Otorhinolaryngology-Head and Neck Surgery, Dankook University College of Medicine, Cheonan, Republic of Korea

Abstract

Background and Objectives
Anaplastic thyroid carcinoma (ATC) is one of the lethal human neo plasms. Photodynamic therapy (PDT) is based on the interaction of a photosensitizer and light with a specific wavelength, and induces destruction of cancer cells. The purpose of this study is to evaluate the effect of the PDT with photofrin on SNU-80 anaplastic thyroid cancer cells.
Materials and Methods
After PDT, cell viability was measured by MTT assay. The experiments were done at photofrin concentration of 1.6 to 3.2 μg/ml. Subcellular localization of photofrin were observed by ER-TrackerTM and Mito Tracker® . Hoechst and propidium iodide (PI) double stained cells were analyzed to measure the cellular apoptosis and necrosis using confocal microscope at 4, 8, and 24 hours after laser irradiation. Caspase activation was measured by western blot analysis.
Results
Cytotoxicity was increased accordingly to increasing photofrin concen tration in MTT assay. The photofrin was localized at cytoplasm and mitochondria inside SNU-80 cells. Apoptosis and necrosis cells were increased on confocal microscope, as time after irradiation was progressed. The expression of caspase-3, -9 and poly (ADP-ribose) polymerase (PARP) were detected by Western blot analysis indicating that Photoprin-PDT showed cytotoxicity to anaplastic thyroid cancer cells in dose-dependent pattern.
Conclusion
Photofrin-PDT led to in vitro cell death of SNU-80 cells through mito chondrial mediated apoptosis. PDT could be used as a part of multimodal treatment for ATC.

Keyword

Photodynamic therapy; Anaplastic thyroid carcinoma
Full Text Links
  • ML
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr